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Objective. This study was designed to investigate whether leptin modiﬁes angiotensin (Ang) II-induced proliferation of aortic
vascularsmoothmusclecells(VSMCs)from10-week-oldmaleWistarandspontaneouslyhypertensiverats(SHR),andthepossible
role of nitric oxide (NO). Methods. NO and NO synthase (NOS) activity were assessed by the Griess and 3H-arginine/citrulline
conversionassays,respectively.InducibleNOS(iNOS)andNADPHoxidasesubutnitNox2expressionwasdeterminedbyWestern-
blot.TheproliferativeresponsestoAngIIwereevaluatedthroughenzymaticmethods.Results.LeptininhibitedtheAngII-induced
proliferative response of VSMCs from control rats. This inhibitory eﬀect of leptin was abolished by NOS inhibitor, NMMA,
and iNOS selective inhibitor, L-NIL, and was not observed in leptin receptor-deﬁcient fa/fa rats. SHR showed increased serum
leptin concentrations and lipid peroxidation. Despite a similar leptin-induced iNOS up-regulation, VSMCs from SHR showed
an impaired NOS activity and NO production induced by leptin, and an increased basal Nox2 expression. The inhibitory eﬀect
of leptin on Ang II-induced VSMC proliferation was attenuated. Conclusion. Leptin blocks the proliferative response to Ang II
through NO-dependent mechanisms. The attenuation of this inhibitory eﬀect of leptin in spontaneous hypertension appears to
be due to a reduced NO bioavailability in VSMCs.
1.Introduction
Hypertension is associated with structural changes in blood
vessels known as “vascular remodelling” that include an
altered proliferation, hypertrophy, migration, and apoptosis
of vascular smooth muscle cells (VSMCs), together with an
increased extracellular matrix abundance [1]. Angiotensin
(Ang II) constitutes one of the main factors involved in
vascular remodelling during the onset of hypertension [1].
Angiotensin II exerts pleiotropic actions on the vasculature,
such as vasoconstriction, VSMC migration, proliferation
and hypertrophy, increased extracellular matrix formation,
and activation of NAD(P)H oxidases [1, 2]. Through these
actions Ang II promotes vascular inﬂammation as well as
endothelial dysfunction and structural remodelling.
Leptin, the obesity gene (ob) product, participates in the
control of body weight by regulating food intake and energy
expenditure [3, 4]. In addition to the maintenance of energy
homeostasis, leptin induces a balanced eﬀect on the control
ofbloodpressure(BP)withapressorresponseattributableto
sympathetic activation via the central nervous system and a
depressor response due to a direct eﬀe c to fl e p t i no np e r i p h -
eral tissues [5]. Leptin increases the vasomotor sympathetic
activity through the activation of leptin receptors (OB-R)
in the ventromedial and dorsomedial hypothalamic regions
[6]. On the other hand, leptin exerts a direct vasodilation2 Mediators of Inﬂammation
through diﬀerent mechanisms, which include the release of
endothelial nitric oxide (NO) in the aorta and coronary
arteries [7–9] and endothelium-derived hyperpolarizing
factor (EDHF) in mesenteric arteries [8, 10], as well as
the inhibition of the Ang II-induced calcium increase and
vasoconstriction in the smooth muscle layer of the aorta via
NO [11]. A further mechanism whereby leptin decreases BP
is related to the induction of natriuresis and diuresis at the
tubular level through NO-dependent mechanisms [12, 13].
Increased circulating concentrations of leptin are found in
hypertensive animal models [14, 15] and humans [16, 17],
suggesting a possible link between hyperleptinemia, and
cardiovascular dysfunction in hypertension. In this respect,
it has recently been reported that the beneﬁcial vascular,
renal and cardiac responses induced by leptin are impaired
in hypertensive rats [10, 12, 14, 15].
Leptin has been suggested to participate in vascular
remodelling, since it induces the proliferation of rat aortic
VSMCs [18] and promotes neointimal growth of VSMCs
after injury in mice [19]. Nonetheless, these data are
not univocal, given that other authors have reported that
leptin inhibits cell growth of human VSMCs [20]. These
contradictory observations raise some doubts as regards the
potential involvement of leptin in vascular remodelling. The
present study was designed to examine the eﬀect of leptin
on basal and Ang II-induced proliferation of aortic VSMCs
obtained from normotensive Wistar rats and age-matched,
spontaneously hypertensive rats (SHR). Some experiments
were performed upon VSMCs obtained from Zucker fa/fa
rats to conﬁrm whether the eﬀects of leptin are mediated via
OB-R. To gain further insight into the potential role of NO
in the proliferative response induced by leptin, the eﬀect of
leptin on NO production, NO synthase (NOS) activity and
inducible NOS (iNOS) expression was measured directly in
VSMCs. Moreover, to further corroborate the participation
of NO in the vascular actions of leptin, the eﬀect of the NG-
monomethyl-L-arginine (NMMA), a nonselective inhibitor
of NOS, and L-N6-(1-iminoethyl)-lysine (L-NIL), a selective
inhibitor of iNOS, on the inhibitory eﬀect of leptin on the
Ang II-induced proliferation of VSMC of the aorta was
analyzed.
2.MaterialsandMethods
2.1. Animals. Age-matched (10-week-old) male normoten-
sive Wistar (breading house of the University of Navarra),
SHR and leptin receptor-deﬁcient Zucker fa/fa rats (Harlan,
Barcelona, Spain) were used in the present study. Rats
were maintained under controlled conditions of room
temperature (RT) (20 ± 2◦C), relative humidity (50 ± 10%),
ventilation (at least 15 complete changes of air/h), and artiﬁ-
cial light-dark cycle (lights on from 08:00a.m.–08:00p.m.).
Animals had free access to tap water and fed ad libitum
with an isoenergetic (13.39MJ/kg), isoproteic (14%) rodent
maintenance diet containing 0.13% sodium (2014S Teklad
Global 14% Protein Rodent Maintenance Diet, Harlan).
All experimental procedures conformed to the European
Guidelines for the Care and Use of Laboratory Animals
(Directive 86/609/EEC) and were approved by the Ethical
Committee for Animal Experimentation of the University of
Navarra (036/03). After regular overnight feeding, rats were
sacriﬁced by decapitation in a nonfasted state, since fasting
hasbeenshowntoreducecirculatingconcentrationsofleptin
[4]. Blood samples were immediately collected, and sera
were obtained by cold centrifugation (4◦C) at 700g for 15
minutes. The thoracic aorta was carefully excised, dissected
out, and processed for each study.
2.2. Blood Measurements. Serum glucose concentrations
were measured using a sensitive-automatic glucose sensor
(Ascensia Elite, Bayer, Barcelona, Spain). Serum concen-
trations of triglycerides, total cholesterol (Inﬁnity, Thermo
Electron Corporation, Melbourne, Australia), and free fatty
acids (FFA) (WAKO Chemicals, GmbH, Neuss, Germany)
were measured by enzymatic methods, using available com-
mercial kits. Insulin and leptin were determined by ELISA
(Crystal Chem, Inc., Chicago, IL, USA). Intra- and interassay
coeﬃcients of variation for measurements of insulin and
leptin were 3.5% and 6.3%, respectively, for the former, and
5.4% and 6.9%, for the latter. Lipid peroxidation, as an
indicator of oxidative stress, was estimated by the measure-
ment of thiobarbituric acid reactive substances (TBARS) in
serum as previously described by Conti et al. [21]w i t hs o m e
modiﬁcations. Serum malondialdehyde (MDA), the best-
known speciﬁc TBARS, was used as indicator of lipid per-
oxidation and oxidative stress. FiveμL of serum samples or
standardMDA(Sigma,St.Louis,MO,USA)weremixedwith
120μL of diethyl thiobarbituric acid (DETBA) 10mmol/L
and vortexed for 5 seconds. The reaction mixture was then
incubated at 95
◦C for 60 minutes. After cooling to room
temperature (RT) for 5 minutes, DETBA-MDA adducts were
extracted in 360μL n-butanol (Panreac, Barcelona, Spain)
vortexing for 1 minute and centrifuged at 1,600g for 10
minutes at RT. Then, the chromophore of the DETBA-MDA
adduct was quantiﬁed in 200μL of the upper butanol phase
by ﬂuorescence emission at 535nm with an excitation at
590nm. MDA equivalents (TBARS) were quantiﬁed using
a calibration curve prepared using MDA standard working
solutions.
2.3. Isolation of Vascular Smooth Muscle Cells. Primary
VSMCs were obtained from the thoracic aorta by the tissue
explants method, as previously described [11, 15]. Brieﬂy,
the smooth muscle tissue was longitudinally opened and
cut in small pieces that were grown in plastic 6-well plates
and maintained at 37
◦C in a humidiﬁed incubator with
an atmosphere of 95% air, 5% CO2. Tissue explants were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 20% fetal bovine serum (FBS) (Life Technologies,
Inc., Gaithersburg, MD, USA) and antibiotic-antimycotic
products (10,000U/mL penicillin G sodium, 10,000μg/mL
streptomycin sulfate, and 25μg/mL amphotericin B as
Fungizonein0.85%saline)(LifeTechnologies).Themedium
was changed initially after 24 hours, and then every 2-3 days.
After about 8–10 days, when cells had formed a conﬂuent
monolayer,theywereharvestedbyadditionof0.05%trypsin,Mediators of Inﬂammation 3
and the culture was continued up to 4–6 passages using
DMEM containing 10% FBS.
2.4. Cell Proliferation Assay. Cell proliferation of VSMCs
was measured using the CellTiter 96 Aqueous One Solution
cell proliferation assay (Promega, Charbonnier, France),
according to the manufacturer’s instructions. VSMCs were
plated in 96-well plate (3,500 cell per well) and incubated
for 24 hours in DMEM containing 10% FBS. Quiescence was
induced by incubating the cells in DMEM containing 0.1%
FBS for 48 hours. Serum-deprived VSMCs were stimulated
for 72 hours with diﬀerent concentrations of Ang II (0.1–
1,000nmol/L) (Sigma) in order to obtain a concentration-
response curve for the determination of the pD2 value.
In a second subset of experiments, cells were incubated
with diﬀerent concentrations of leptin (0.1–100nmol/L)
(PreproTech EC, Inc., Rocky Hill, NJ, USA) for 72 hours
in the absence or presence of Ang II (100nmol/L). In
a third subset of experiments, cells were stimulated with
leptin (10nmol/L) for 72 hours in the presence of Ang II
(100nmol/L) and NMMA (10μmol/L) (Sigma) or L-NIL
(10μmol/L) (Sigma). The concentration of leptin as well
as the pharmacological NOS inhibitors to carry out the
experiments was chosen on the basis of prior experiments
performed in our laboratory [11, 15]. Following the cell
treatment, 20μL of CellTiter 96 Aqueous One Solution
were added to each well and the plate was incubated in
the darkness at 37
◦C for 4 hours. Optical densities were
measured at 490nm using a microplate reader (Sunrise,
Tecan, Germany). Proliferative values were expressed as
percentage of proliferation of treated cells compared to basal
proliferation of unstimulated cells.
2.5. Western-Blot Analyses. Quiescent VSMCs were stimu-
lated for 30 minutes with leptin (10nmol/L). At diﬀerent
times of the stimulation (0, 10, 20, and 30 minutes), cells
were harvested and homogenized in ice-cold lysis buﬀer
(0.1% SDS, 1% Triton X-100, 5mM EDTA·2H2O, 1 M Tris-
HCl, 150mM NaCl, 1% sodium deoxycholate, pH 7.40)
supplemented with a protease inhibitor cocktail (Complete
Mini-EDTAfree,Roche,Mannheim,Germany).Lysateswere
centrifuged at 16,000g at 4◦C for 15 minutes. Total protein
concentrations were determined by the Bradford assay [22],
using bovine serum albumin (BSA) (Sigma) as standard
[23]. Thirty micrograms of total protein were diluted
in loading buﬀer 4X (20% β-mercaptoethanol, 40mmol/L
dithiothreitol, 8% SDS, 40% glycerol, 0.016% bromophenol
blue, 200mmol/L Tris-HCl, pH 6.80) and heated for 10
minutes at 100
◦C. Samples were run out in 8% SDS-PAGE,
subsequently transferred to nitrocellulose membranes (Bio-
Rad Laboratories, Inc., Hercules, CA, USA) and blocked in
Tris-buﬀeredsaline(10mmol/LTris-HCl,150mmol/LNaCl,
pH 8.00) with 0.05% Tween 20 (TBS-T) containing 5%
nonfat dry milk for 1 hour at RT. Blots were then incubated
overnight at 4◦C with rabbit polyclonal anti-Akt1, rabbit
polyclonal anti-phospho-(Thr308)-Akt (Upstate, Lake Placid,
NY, USA), rabbit polyclonal anti-STAT3, rabbit polyclonal
anti-phospho-(Tyr705)-STAT3 (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), mouse monoclonal anti-
iNOS (BD Transduction Laboratories, San Jose, CA, USA),
rabbit polyclonal anti Nox2/gp91phox (Abcam, Cambridge,
UK), or murine monoclonal anti-β-actin (Sigma) antibod-
ies. The antigen-antibody complexes were visualized using
peroxidase-conjugated antirabbit or antimouse antibodies
(1:5,000) and the enhanced chemiluminescence ECL detec-
tionsystem(AmershamBiosciences,Buckinghamshire,UK).
The intensity of the bands was determined by densitometric
analysis and normalised with β-actin density values.
2.6. Evaluation of NO Production and NOS Activity. Qui-
escent VSMCs were stimulated during 30 minutes with
leptin (10nmol/L) in the presence or absence of NMMA
(10μmol/L)orL-NIL(10μmol/L).Onesampleperassaywas
used to obtain control responses in the presence of solvent.
Samplesoftheculturemediawerecollectedatdiﬀerenttimes
(0, 10, 20 and 30 minutes) for the measurement of nitrates
and nitrites ([NOx]), as an index of NO production, with a
commercial kit (Cayman Chemical, Ann Arbor, MI, USA)
based on the Griess reaction following the manufacturer’s
protocol. The intra- and inter-assay coeﬃcients of variation
were 3.3% and 6.5%, respectively. Stimulated cells were
harvestedandhomogenisedinalysisbuﬀer(25mmol/LTris,
1mmol/L EDTA, 1mmol/L EGTA; pH 7.40) supplemented
with a protease inhibitor cocktail (Roche) for the determina-
tionofNOSactivity.Theproteincontentofthehomogenates
was determined by the method of Bradford [22]. NOS activ-
ity was measured by the L-[3H]arginine to L-[3H]citrulline
conversion assay, using a commercial kit (Stratagene, La
Jolla, CA, USA). The intra- and inter-assay coeﬃcients of
variation were 6.3% and 9.1%, respectively. Brieﬂy, samples
of 20μg of protein were incubated at room temperature
(RT) for 1 hour in the reaction buﬀer [25mmol/L Tris-HCl
(pH 7.40), 3μmol/L tetrahydrobiopterin, 1μmol/L FADH,
1μmol/L FMNH2, 1mmol/L NADPH, 0.6mmol/L CaCl2]
supplemented with L-[3H]arginine (1μCi/μL) (Amersham
Biosciences). L-[3H]citrulline was quantiﬁed by using a
scintillation counter (Wallac 1409 DSA, PerkinElmer, Inc.,
Barcelona, Spain). All assays were performed in duplicate.
2.7. Statistical Analysis. Data are presented as mean ±
standard error of the mean (SEM). Concentration-response
curves were ﬁtted by nonlinear regression, the concentration
giving 50% of the maximal response (EC50) was determined,
and the pD2 was calculated as −log EC50 (mol/L). Statistical
diﬀerences among mean values were determined using the
two-way ANOVA, one-way ANOVA followed by Dunnett’s
t test, or the Student’s t test, where appropriate. A P value
< .05 was considered statistically signiﬁcant. Analyses were
performed by the SPSS/Windows version 15.0.1 software
(SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Metabolic Proﬁle and Serum Leptin Concentrations. Gen-
eral characteristics of the carbohydrate and lipid metabolism
of experimental animals are shown in Table 1.S H Rw e r e4 Mediators of Inﬂammation
Table 1: Metabolic characteristics of normotensive and hyperten-
sive animals.
Determination Wistar rats
(n = 14) SHR (n = 28) P value
Body weight (g) 283.6 ±9.4 303.3 ±2.6 .001
Free fatty acids (mg/dL) 20.8 ±1.72 0 .3 ±0.9 .776
Triglycerides (mg/dL) 105.3 ±19.2 129.5 ±6.7 .05
Total cholesterol (mg/dL) 113.5 ±6.4 134.1 ±3.2 .002
Glucose (mg/dL) 133.4 ±0.7 205.5 ±0.5 .002
Insulin (ng/mL) 1.3 ±0.33 .0 ±0.3 .001
Leptin (ng/mL) 2.5 ±0.13 .1 ±0.1 .05
TBARS (μmol/L) 1.4 ±0.22 .2 ±0.2 .025
SHR, spontaneously hypertensive rats; TBARS, thiobarbituric acid reactive
substances. Values presented as the mean ± SEM. Diﬀerences between
groups were analysed by Student’s t-test. Bold values are statistically
signiﬁcant P values among groups.
heavier (P<. 001) and exhibited higher serum glucose (P<
.01) and insulin (P<. 001) concentrations than age-matched
Wistar rats. Serum triglycerides and total cholesterol were
also increased (P<. 05 and P<. 01, resp.) in SHR, compared
to Wistar rats. The circulating concentrations of leptin were
increased (P<. 05) in the SHR group. A positive correlation
between serum leptin levels and body weight (r = 0.67, P<
.0001) was found. The serum levels of TBARS, as the index
of oxidative stress, were signiﬁcantly (P<. 05) increased in
SHR compared to control rats.
3.2. Eﬀe c to fL e p t i no nA n gI I - I n d u c e dP r o l i f e r a t i v eR e s p o n s e
in VSMCs. Ang II elicited a concentration-dependent (P<
.00001) increase in the proliferation of aortic VSMCs
obtained from Wistar rats (pD2 = 9.1 ± 0.6) (Figure 1). A
concentration of Ang II 100nmol/L, inducing a proliferative
response of 193 ± 17% compared to basal proliferation, was
chosen for subsequent experiments.
All the tested leptin concentrations signiﬁcantly inhib-
ited (P<. 05) the basal proliferation of aortic VSMCs
from Wistar rats (Figure 2(a)). Moreover, leptin induced a
decrease (P<. 01) in Ang II-induced proliferative response
i nV S M C sf r o mW i s t a rr a t s( Figure 2(b)). To test that the
inhibitory eﬀect of leptin is mediated via its binding to
leptin receptors, the experiments were also performed in
VSMCs obtained from Zucker fa/fa rats, a genetic model
of leptin receptor resistance. As earlier reported by other
authors [24, 25], Zucker fa/fa rats were severely obese, and
showed hyperglycaemia, hyperinsulinemia, hyperlipidemia,
and hyperleptinemia (Table 2). No inhibitory eﬀect of leptin
(P = .409) was observed on Ang II-induced proliferation
in VSMCs obtained from the aorta of Zucker fa/fa rats
(Figure 2(c)).
To determine whether this vascular action of leptin
may be altered in hypertension, we assessed the eﬀect of
leptin on Ang II-induced proliferative response in aortic
VSMCs from SHR rats. Although leptin was able to inhibit
(P<. 01) the Ang II-induced proliferation in VSMCs from
SHR (Figure 2(d)), the reduction of the response to Ang
B
a
s
a
l
p
r
o
l
i
f
e
r
a
t
i
v
e
r
e
s
p
o
n
s
e
(
v
e
r
s
u
s
u
n
s
t
i
m
u
l
a
t
e
d
c
e
l
l
s
%
)
225
200
175
150
125
100
75
50
25
0
Ang II (nmol/L)
00 .1 1 10 100 1000
∗∗
∗∗∗ ∗∗∗
∗∗∗ ∗∗∗
Figure 1: Concentration-response curve of the proliferation
induced by angiotensin (Ang) II in aortic vascular smooth muscle
cells (VSMCs) obtained from Wistar rats. Values are the mean ±
SEM (n = 10–15). Diﬀerences between groups were analysed by
one-way ANOVA followed by Dunnet’s test. ∗∗P<. 01, ∗∗∗P<. 001
versus control response in unstimulated cells.
Table 2: Metabolic characteristics of Zucker fa/fa rats.
Determination Wistar rats
(n = 14)
Zucker fa/fa
rats (n = 10) P value
Body weight (g) 283.6 ± 9.4 403.1 ± 4.9 .00001
Free fatty acids (mg/dL) 20.8 ± 1.7 15.7 ± 2.1 .081
Triglycerides (mg/dL) 105.3 ± 19.2 285.1 ± 16.6 .00001
Total cholesterol (mg/dL) 113.5 ± 6.4 131.4 ± 2.1 .05
Glucose (mg/dL) 133.4 ± 0.7 166.8 ± 1.1 .05
Insulin (ng/mL) 1.3 ± 0.3 10.8 ± 0.4 .00001
Leptin (ng/mL) 2.5 ± 0.1 49.8 ± 0.3 .00001
Values presented as the mean ± SEM. Diﬀerences between groups were
analysed by Student’s t test. Bold values are statistically signiﬁcant P values
among groups.
II was lower than that of control Wistar rats in all tested
concentrationsofleptin(0.1nmol/L,18±6%versus28±4%;
1nmol/L,17±5% versus28±3% versus17±5%;10nmol/L,
15±6% versus 31±3%; 100nmol/l, 41±2% versus 24±8%,
resp.).
3.3. Eﬀect of Leptin on Ang II-Induced Proliferation of VSMCs
in the Presence of NOS Inhibitors. Our group previously
describedthatleptininducesthesynthesisofNOthroughthe
activation of iNOS in VSMCs [11]. The eﬀect of leptin on
the Ang II-induced proliferative response of aortic VSMCs
obtained from Wistar rats was reexamined in the presence of
the NOS inhibitor, NMMA, or the iNOS selective inhibitor,
L-NIL. The concentration of leptin 10nmol/L, reducing
by ∼15% the basal proliferation and by ∼30% the Ang
II-induced proliferation in aortic VSMCs, was chosen to
carryouttheseexperiments.BothNOSinhibitorscompletely
abolished the inhibitory eﬀect of leptin on the Ang II-
mediated proliferation (Figure 3). Moreover, the presence ofMediators of Inﬂammation 5
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Figure 2: Eﬀect of leptin on basal and Ang II-induced proliferation of aortic VSMCs. Aortic VSMCs obtained from Wistar rats were
incubated for 72 hours with increasing concentrations of leptin (0.1–100nmol/L) in the absence (a) or presence (b) of Ang II (100nmol/l),
andtheproliferativeresponsewasmeasuredusingatetrazoliumdye(MTT)-basedproliferationassay.EﬀectofleptinonAngII(100nmol/l)-
induced proliferation in VSMCs obtained from the aorta of leptin receptor-deﬁcient Zucker fa/fa rats (c) and spontaneously hypertensive
rats (SHR). Values are the mean ± SEM (n = 40). Diﬀerences between groups were analysed by one-way ANOVA followed by Dunnet’s test.
∗P<.05, ∗∗∗P<.001 versus control response in unstimulated cells (a) or to Ang II (b, c).
NMMA or L-NIL blunted the inhibition of basal prolifer-
ation induced by leptin (105 ± 1% and 107 ± 2% versus
85 ± 2%mg, resp.). Basal and Ang II-induced proliferation
of aortic VSMCs was not aﬀected by the presence of NOS
inhibitors.
3.4. Impaired NOS Activity and NO Production in VSMCs
in Hypertensive Rats. The activation of the JAK2/STAT3 and
PI3K/Akt pathways constitutes an early step for the up-
regulation of iNOS induced by leptin [11, 26, 27]. The
ability of leptin to trigger JAK2/STAT3 and PI3K/Akt was
examined by the degree of phosphorylation/activation of the
downstream molecules STAT3 and Akt after leptin treatment
in VSMCs from Wistar rats and SHR. Leptin activated the
phosphorylation of STAT3 in a time-dependent manner,
whereas a maximal phosphorylation of Akt was observed
after 10 minutes of leptin stimulation with attenuation
of the phosphorylation thereafter (Figures 4(a) and 4(b)).
No diﬀerences between VSMCs from Wistar and SHR
were found for the activation/phosphorylation of Akt and
STAT3. Accordingly, leptin induced a signiﬁcant increase
in iNOS expression in aortic VSMCs from Wistar and
SHR (Figure 4(c)). Nevertheless, the ability of leptin to
induce NO production and NOS activity was impaired
in aortic VSMCs obtained from SHR (Figures 5(a) and
5(b)). It is well known that enhanced production of NO-
scavenger substances such as reactive oxygen species (ROS)6 Mediators of Inﬂammation
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Figure 3: Impact of NOS inhibitors on the inhibitory eﬀect of leptin on Ang II-induced proliferation of aortic VSMCs. The coincubation
with both NOS inhibitor, NMMA (10μmol/l), (a) and the selective iNOS inhibitor, L-NIL (10μmol/l), (b) blunted the inhibitory eﬀect of
leptin (10nmol/l) on the Ang II (100nmol/l)-induced proliferative response in aortic vascular smooth muscle cells (VSMCs) from Wistar
rats. Data are expressed as mean ± SEM (n=40). Diﬀerences between groups were analysed by two-way ANOVA. In case of interaction
between factors (leptin treatment and NOS inhibitors), diﬀerences between groups were analysed by one-way ANOVA followed by Dunnet’s
test. ∗P<. 05, ∗∗P<. 01 versus control response to Ang II in the absence of inhibitors.
under spontaneous hypertension is involved in reducing NO
bioavailability [2]. Thus, we compared the basal expression
of Nox2, a subunit of the ROS-generating NADPH oxidase,
in VSMCs from control Wistar rats and SHR. The protein
levels of Nox2 were signiﬁcantly (P<. 05) increased in
V S M C sf r o mh y p e r t e n s i v er a t s( Figure 5(c)).
4. Discussion
The smooth muscle layer represents an important target
for the vascular eﬀects of leptin [11, 15]. This adipokine
decreases passive wall tension and Ang II-induced vaso-
constriction operating directly on VSMCs [11]. Despite the
growing evidence supporting the depressor action of leptin
on blood vessels, the role of leptin on vascular remodelling
remains unclear [18–20]. Thus, the present study has further
explored the mechanisms whereby leptin participates in the
proliferationofVSMCs,acrucialprocessinvolvedinvascular
remodelling.
Our results show that leptin inhibits the basal prolifera-
tion of aortic VSMCs in Wistar rats, which is in concordance
with ﬁndings reported by Bohlen and colleagues using
human aortic VSMCs [20]. Moreover, we show, for the ﬁrst
time, that leptin inhibits the Ang II-induced cell growth
of VSMCs. To test directly whether this inhibitory eﬀect is
dependent on leptin signalling, the experiments were also
performed in VSMCs obtained from the aorta of Zucker
fa/fa rats, an animal model with a missense mutation in the
leptin receptor gene (OB-R269gln→pro) that results in both a
reduced aﬃnity for leptin and reduced signal transduction
capability [24, 25]. As a result of this genetic leptin receptor
resistance, Zucker rats show severe metabolic alterations,
including severe obesity, hyperglycemia, hyperinsulinemia,
insulin resistance, and hypogonadism [24, 25]. This animal
model of leptin resistance, that is, the obese Zucker fa/fa
rats, also shows hypogonadism that further aggravates the
obesephenotype,sinceleptincanregulatetheexpressionand
secretion of gonadotropins, and the hypothalamic-pituitary-
gonadal axis is closely associated to food intake, body weight,
and fat distribution [28]. In the present study, our ﬁndings
showed the lack of eﬀect of leptin on Ang II-induced
proliferation in aortic VSMCs from Zucker rats, suggesting
that functional leptin receptors are required for this vascular
eﬀect of the hormone.
A functional relation between leptin and NO has been
established in blood vessels [7, 8, 11, 29]. Fr¨ uhbeck showed
that intravenous administration of leptin in rats with
autonomic blockade induces a systemic vasodilation that is
associated with an increase of serum [NOx]a n dr e v e r s e d
with Nω-nitro-L-arginine methyl ester [7]. Further studies
have shown that leptin induces an endothelial-dependent
vasodilation by activating a PI 3-kinase-independent Akt-
endothelial NOS (eNOS) phosphorylation pathway [29, 30].
Moreover, leptin treatment in vivo has been shown to
reverse the endothelial dysfunction of leptin-deﬁcient obese
(ob/ob) mice by increasing NO bioavailability in vessels [31].
This adipokine decreases passive wall tension and Ang II-
induced vasoconstriction by up-regulating iNOS through
mechanisms involving JAK2/STAT3 and PI3K/Akt pathwaysMediators of Inﬂammation 7
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Figure 4: Eﬀect of leptin activation of Akt and STAT3 and iNOS expression in aortic VSMCs. Bar graphs show the diﬀerences in the time
course of Akt (a) and STAT3 (b) activation/phosphorylation as well as iNOS (c) protein expression in leptin (10nmol/L)-stimulated aortic
VSMCs from Wistar and SHR. Data are expressed as mean ± SEM (n = 10). Diﬀerences between groups were analysed by two-way ANOVA.
In case of interaction between factors (strain and time of leptin stimulation), diﬀerences between groups were analysed by one-way ANOVA
followed by Dunnet’s test ∗P<.05, ∗∗P<.01 versus unstimulated cells.
in VSMCs [11]. The ability of leptin to induce iNOS
gene expression has been shown in several cell types, such
as murine J774A.1 macrophages, rat adipocytes, human
primary chondrocytes and ATDC5 cells, C6 glioma cell line,
and human OA cartilage [26, 27, 32–34]. Our ﬁndings
showed that the inhibitory eﬀect of leptin on Ang II-
induced cell growth of VSMCs is completely prevented by
an iNOS inhibitor. Previous data reported by our group
provided evidence that the depressor action of leptin in the
smooth muscle layer of the aorta takes place by reducing the
vasoconstrictor potential of Ang II through NO-dependent
mechanisms [11]. Similar ﬁndings of hypotensive eﬀects of
l e p t i nv i aN Oh a v eb e e nr e p o r t e di nr a tm y o c a r d i u m[ 35],
kidneys[13], endothelium of conduit vessels (aorta) [8, 29,
30],and resistance vessels (mesenteric and coronary arteries)
[8, 9]. Taken together, these data support the notion that
NO represents a key mediator of the cardiovascular eﬀects
of leptin.
SHR constitute a well-known model of essential hyper-
tension that becomes hypertensive at an early stage (4–6
weeksofage)[36].Earlyvascularremodellingexperiencedby
the aorta of SHR leads to a reduced contractility in vitro and,8 Mediators of Inﬂammation
[
N
O
x
]
(
μ
m
o
l
/
L
)
12
10
8
6
4
2
0
∗∗
Wistar SHR
Control
Leptin 10nmol/L
(a)
N
O
S
a
c
t
i
v
i
t
y
(
o
f
c
o
n
t
r
o
l
%
)
250
200
150
100
50
0
∗∗
Wistar SHR
Control
Leptin 10nmol/L
(b)
N
o
x
2
p
r
o
t
e
i
n
/
β
-
a
c
t
i
n
0.3
0.25
0.2
0.15
0.1
0.05
0
∗
Wistar SHR
Nox2
β-actin
−65kDa
−42kDa
(c)
Figure 5: Impaired NO production and NOS activity and increased NADPH oxidase expression in aortic VSMCs from hypertensive rats.
Bar graphs show (a) the accumulation of NOx in the culture media and (b) the NOS activity of aortic VSMCs from control Wistar rats
and spontaneously hypertensive rats (SHR) stimulated with leptin (10nmol/l) for 30 minutes. (c) Basal expression of Nox2, a subunit of the
NADPHoxidase,inVSMCsfromcontrolWistarratsandSHR.Dataareexpressedasmean ±SEM(n =10).Diﬀerencesbetweengroupswere
analysed by two-way ANOVA (a, b) or Student’s t test (c). In case of interaction between factors (strain and leptin treatment), diﬀerences
between groups were analysed by one-way ANOVA followed by Dunnet’s test ∗P< .05, ∗∗P<.01 versus control response in unstimulated
cells (a, b) or VSMCs from control rats (c).
probably, to vascular rigidity in vivo [2, 15]. Overactivation
of the renin-angiotensin system constitutes an important
contributor to the vascular remodelling associated with the
onset of hypertension in SHR [1]. Touyz and colleagues [37]
reported that Ang II concentration dependently increased
the 3H tymidine incorporation in VSMCs, as an index
of synthesis of DNA and cell proliferation, with enhanced
responsiveness in VSMCs from SHR compared to control
rats. In the present study, SHR showed features of the
human metabolic syndrome, such as overweight, hypergly-
caemia, hyperinsulinemia, insulin resistance, dyslipidemia,
and increased circulating concentrations of leptin, which
conﬁrm data reported by our group and others [12, 38].
Moreover, our results show that aortic VSMCs from SHR
are less responsive to the inhibitory eﬀect of leptin on Ang
II-induced proliferation. These ﬁndings are in agreement
with other studies reporting an impairment of the depressor
actions of leptin (or leptin resistance) under spontaneous
hypertension in rat myocardium [14], mesenteric arter-
ies [10], aorta [15], and kidneys [12]. Interestingly, we
found that, despite a similar activation of JAK2/STAT3
and PI3K/Akt and increased expression of iNOS than that
observed in normotensive rats, VSMCs from SHR showed an
impairedNOSactivityandNOproductioninducedbyleptin
as well as higher basal Nox2 expression, a subunit of the
reactive oxygen species (ROS)-producing NADPH oxidases.
It is well known that endothelial dysfunction in SHR is char-
acterized by a reduced synthesis and release of endothelium-
derived relaxing factors, such as NO and/or an enhanced
production of reactive oxygen species (ROS), which scavenge
NO within vessels to reduce its biological half-life [2]. In
VSMCs, Ang II reportedly increased the ROS-generating
enzymes NADPH oxidases and ROS function as important
intra-andintercellularsecondmessengerstomodulatemany
downstream signalling molecules, such as protein tyrosine
phosphatases (PTPs), protein tyrosine kinases, transcription
factors,mitogen-activated protein kinases (MAPKs),and ion
channels, leading to VSMCs growth and migration [2]. In
the present study, our data showed an increased systemic
oxidative stress as well as higher expression levels in VSMCs
of Nox2 in hypertensive rats. Together, it could be speculated
that, in the setting of hypertension, the antiproliferative
eﬀectsofleptinareoverriddenbytheeﬀectsofAngII,despite
the hyperleptinemia. Among the diﬀerent mechanisms that
may underlie this ﬁnding, the role of Ang II-induced
production of ROS could be important in experimental
hypertension.
In conclusion, our results provide evidence that leptin
constitutes a negative modulator of vascular remodelling.
This statement is supported by ﬁndings reported herein: (a)
leptin inhibits the basal and Ang II-induced proliferative
response of VSMCs through NO-dependent mechanisms;
(b) the lack of eﬀect of leptin on Ang II-stimulated prolif-
eration in VSMCs obtained from leptin receptor-deﬁcient
Zucker fa/fa rats provides evidence that functional leptin
receptors (OB-R) are required for this inhibition; (c) the
impairment of the inhibitory eﬀect of leptin on Ang II-
induced proliferation of VSMC from SHR appears to be
a consequence of a reduced NO biodisponibility due to
an increased expression of NADPH oxidases. Therefore,
hyperleptinemia may arise as a compensatory mechanism to
overcome vascular leptin resistance in SHR.Mediators of Inﬂammation 9
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